Immunomodulatory compounds and methods of use thereof

Details Immunomodulatory compounds and methods of use thereof Immunomodulatory compounds and methods of use thereof

2005-03-09

2010-11-16

Olson, Eric S (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S104000, C562S012000, C562S014000, C562S020000

Reexamination Certificate

active

07833993

ABSTRACT:
The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.

REFERENCES:
patent: 5484911 (1996-01-01), Hong et al.
patent: 5635188 (1997-06-01), Bystryn
patent: 5681824 (1997-10-01), Christ et al.
patent: 5895653 (1999-04-01), Eibl et al.
patent: 5904925 (1999-05-01), Exner
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6136797 (2000-10-01), Zilch et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6165502 (2000-12-01), Oleske et al.
patent: 6172049 (2001-01-01), Dwyer et al.
patent: 6180111 (2001-01-01), Stein et al.
patent: 6284267 (2001-09-01), Aneja
patent: 6290973 (2001-09-01), Hawkins et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6355257 (2002-03-01), Johnson et al.
patent: 6437165 (2002-08-01), Mandala et al.
patent: 6461637 (2002-10-01), Rahman
patent: 6521776 (2003-02-01), Hawkins et al.
patent: 6551600 (2003-04-01), Hawkins et al.
patent: 6630161 (2003-10-01), Leesman
patent: 6835721 (2004-12-01), Hawkins et al.
patent: 7416726 (2008-08-01), Ravetch
patent: 7560584 (2009-07-01), Hawkins et al.
patent: 7683200 (2010-03-01), Fang et al.
patent: 2002/0049314 (2002-04-01), Hawkins et al.
patent: 2002/0176861 (2002-11-01), Hawkins et al.
patent: 2003/0153532 (2003-08-01), Hawkins et al.
patent: 2004/0006242 (2004-01-01), Hawkins et al.
patent: 2005/0123566 (2005-06-01), Hawkins et al.
patent: 2005/0164988 (2005-07-01), Hawkins et al.
patent: 2007/0020232 (2007-01-01), Rossignol et al.
patent: 2007/0027111 (2007-02-01), Hawkins et al.
patent: 2007/0292418 (2007-12-01), Fields et al.
patent: 0 390 216 (1990-03-01), None
patent: 02-261866 (1990-10-01), None
patent: WO 93/04672 (1993-03-01), None
patent: WO 95/11700 (1995-05-01), None
patent: WO 98/57659 (1998-12-01), None
patent: WO 98/57659 (1998-12-01), None
patent: WO 00/44758 (2000-08-01), None
patent: WO 00/44758 (2000-08-01), None
patent: WO 00/73263 (2000-12-01), None
patent: WO 01/46127 (2001-06-01), None
patent: WO 01/46127 (2001-06-01), None
patent: WO 01/90129 (2001-11-01), None
patent: WO 01/90129 (2001-11-01), None
patent: WO 02/09752 (2002-02-01), None
patent: WO 02/09752 (2002-02-01), None
patent: WO03/003985 (2003-01-01), None
patent: WO 03/011223 (2003-02-01), None
patent: WO 03/011223 (2003-02-01), None
Gokhale et al., “A n improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxological, and therapeutic evaluation” British Journal of cancer (1996) vol. 74, pp. 43-48.
U.S. Appl. No. 11/605,557, filed Nov. 2006, Fields et al.
Cheung C. W., et al. “American Chemical Society—226thNational Meeting: New drugs highlights: Sep. 7-11, 2003, New York, NY, USA” IDRUGS, (2003) 6/10. pp. 939-942.
Eustache, et al., “New Acyclic Analogues of Lipid A: Synthesis of 4-Phosphonoxybutyl and 3-Phosphonoxypropyl Glycosides of 2-amino-2-deoxy-D-glucose”, Carbohydrate Research, vol. 251, pp. 251-267 (1994).
Jiang Z., et al. “Synthetic vaccines: The role of adjuvants in immune targeting.” Current Medical Chesmistry, (2003) 10/15. pp. 1423-1439.
Hawkins, et al., “A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity”, Journal of Pharmacology and Experimental Therapeutics, vol. 300; No. 2, pp. 655-661 (2002).
Homma, et al., “Structural Requirements of Lipid A Responsible for the Functions: A Study with Chemically Synthesized Lipid A and Its Analogues”, J. Biochem, vol. 98, pp. 395-406 (1985).
Lien, et al., “A Novel Synthetic Acyclic Lipid A-like Agonist Activates Cells via the Lipopolysaccharide/Toll-like Receptor 4 Signaling Pathway”, The Journal of Biological Chemistry, vol. 276, No. 3, pp. 1873-1880 (2001).
Matsuura, et al., “Activity of Monosaccharide Lipid A Analogues in Human Monocytic Cells as Agonists or Antagonists of Bacterial Lipopolysaccharide”, Infection and Immunity, vol. 67, No. 12, pp. 6286-6292 (1999).
Przetak, et al., “Novel Synthetic LPS Receptor Agonists Boost Systemic and Mucosal Antibody Responses in Mice”, Vaccine 21, pp. 961-970 (2003).
Przetak et al., Vaccine, (2003), 21 (9-10), 961-970.
Seydel, et al., “The Generalized Endotoxic Principle”, Eur. J. Immunol., vol. 33, pp. 1586-1592 (2003).
The Merck Manual of Diagnosis and Therapy (17thEd) (1999), p. 1420-1421.
Gokhale et al., “An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological, and therapeutic evaluation,” Br. J. Cancer 74:43-48 (1996).
Hawkins et al., “Inhibition of endotoxins response by synthetic TLR4 antagonists,” Curr. Topics Med. Chem. 4:1147-71 (2004).
Merriam-Webster's Collegiate Dictionary, 10th edition, published 1998 by Merriam-Webster, Inc., p. 924.
Rossignol and Lynn, “TLR4 antagonists for endotoxemia and beyond,” Curr. Opin. Invest. Drugs 6:295-502 (2005).
The Merck Manual of Diagnosis and Therapy, 17th Edition, 1999, published by Merck Research Laboratories, pp. 397-398, 948-949, 1916, and 1979-1981.
The Oxford Textbook of Oncology, 1995, published by Oxford University Press, pp. 447-453.
U.S. Appl. No. 10/157,791, filed May 28, 2002; Office Action Mailed: Sep. 9, 2004.
U.S. Appl. No. 10/157,791, filed: May 28, 2002; Office Action Mailed: Jun. 16, 2005.
U.S. Appl. No. 11/411,564, filed: Apr. 26, 2006; Office Action Mailed: Oct. 2, 2008.
U.S. Appl. No. 11/024,328, filed: Dec. 28, 2004; Office Action Mailed: Sep. 17, 2007.
U.S. Appl. No. 11/024,328, filed: Dec. 28, 2004; Office Action Mailed: Mar. 6, 2008.
U.S. Appl. No. 11/411,332, filed: Apr. 26, 2006; Office Action Mailed: Oct. 25, 2007.
U.S. Appl. No. 11/411,332, filed: Apr. 26, 2006; Office Action Mailed: Jul. 14, 2008.
U.S. Appl. No. 11/605,557, filed: Nov. 28, 2006; Office Action Mailed: Jun. 26, 2008.
Baldridge et al., “Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents,”Exp. Opin. Biol. Ther. 4:1129-1138 (2004).
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
euOverexpressing Human Breast Cancer Xenografts,”Cancer Res. 58:2825-2831 (1998).
Belimezi et al., “Growth inhibiton of breast cancer cell lines overexpressing Her2
eu by a novel internalized fully human Fab antibody fragment,”Cancer Immunol. Immunother. 55:1091-1099 (2006).
Clynes et al., “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,”Nature Med. 6:443-446 (2000).
Coelho et al., “Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2
eu humoral response in mice,”British J. Cancer90:2032-2041 (2004).
Cooper et al., “CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study,”J. Clin. Immunol. 24:693-701 (2004).
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,”Blood103:2738-2743 (2004).
Dalpke et al., “CpG DNA in the Prevention and Treatment of Infections,”Biodrugs16:419-431 (2002).
Eisai Research Inst. Product Datasheet for E6020 or ER-804057 (pp. 1-5; Mar. 1999)..
Hawkins et al., “A Novel Class of Endotoxin Receptor Agonists with Simplified Structure, Toll-Like Receptor 4-Dependent Immunostimulatory Action, and Adjuvant Activity,”J. Pharmacol. Exp. Ther. 300:655-661 (2002).
Jiang and Kogant

Affiliated with

Also associated with

Rating

Immunomodulatory compounds and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunomodulatory compounds and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory compounds and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4169798